Biography
Dr. Chabenne obtained his undergraduate degree in biology and graduate degree in chemistry at Indiana University. His graduate thesis advanced the chemical optimization of glucagon to treat severe hypoglycemia and indirectly initiated the field of glucagon-based co-agonism for treating obesity. He completed a post-doctoral fellowship with Professor Peter Schultz at Ambrx Corporation where he produced biosynthetic analogs of leptin and pharmacologically employed them to restore leptin sensitivity in severely obese rodents. Following his post-doctoral studies, he was employed at AIT Bioscience as a principal investigator for several FDA regulated clinical studies relating to endocrine diseases. Subsequently he joined Novo Nordisk as a senior scientist and established state-of-the-art in vitro assays to assess peptide-based drug candidates and subsequently established a state-of-the-art LCMS facility to support pharmacokinetics of advanced drug candidates. Dr. Chabenne returned to IU as an associate research scientist where is currently focused on employing virally derived insulin-like peptides to advance the structure-activity relationship in the insulin family while searching for novel drug candidates.
